Growth Hormone and the Somatotropic Axis

The somatotropic axis is more committee than solo act

Forty-three amino acids. That's all it takes to make growth hormone-releasing hormone (GHRH), the hypothalamic signal that kicks off one of the most architecturally interesting feedback loops in human endocrinology. I've spent years reading pharmacokinetics papers and the somatotropic axis still makes me stop and appreciate the engineering. A cascade that starts in the brain, loops through the pituitary, bounces signals off the liver, and then regulates itself through negative feedback , all running continuously, with a pronounced nocturnal pulse most people never think about.

This article is about the science of that axis: how it's structured, how growth hormone (GH) is synthesised and secreted, what insulin-like growth factor 1 (IGF-1) does in the relay, and , because this is Australia and the regulatory picture matters , exactly where the law sits on GH-related peptides and compounds.

Architecture of the somatotropic axis

The axis runs in three tiers. At the top, the hypothalamus produces two opposing signals: GHRH (growth hormone-releasing hormone), which stimulates GH secretion from the anterior pituitary, and somatostatin (also called growth hormone-inhibiting hormone, or GHIH), which suppresses it. The balance between these two signals determines when and how much GH the pituitary releases.

At the second tier, somatotroph cells in the anterior pituitary synthesise and secrete GH itself. Human GH (somatotropin) is a 191-amino acid peptide with a molecular weight of roughly 22 kDa. It circulates partly bound to GH-binding protein (GHBP), which is actually the cleaved extracellular domain of the GH receptor and acts as a buffer that extends the hormone's half-life in plasma.

The third tier is the liver; and peripheral tissues, which respond to GH by producing IGF-1. IGF-1 then feeds back negatively on both the hypothalamus (increasing somatostatin tone) and the pituitary (reducing GH release directly). This loop keeps GH secretion from running unchecked. It's an elegant three-way negotiation, and disruption at any point, tumour, receptor mutation, acquired deficiency; has measurable downstream consequences studied in clinical endocrinology for decades.

GH secretion: pulsatile, nocturnal, and age-sensitive

One thing worth understanding: GH is not secreted continuously. It comes out in discrete pulses, typically four to eight per 24-hour period in adults, with the largest pulse occurring shortly after the onset of slow-wave sleep. The amplitude of these pulses is highest during adolescence and declines progressively through adulthood, a physiological pattern that has been well-characterised in the literature since the 1980s.

The pulsatile pattern complicates measurement significantly. A single serum GH reading can be near-zero between pulses in a completely healthy individual, which is why clinical assessment of GH status relies on stimulation testing and IGF-1 levels rather than a single snapshot. Understanding pharmacokinetics here is genuinely non-trivial, GH's plasma half-life is roughly 15 to 20 minutes in its free form, so timing of sampling matters enormously.

A third input layer worth mentioning is ghrelin, the "hunger hormone" produced primarily by gastric cells. Ghrelin acts on growth hormone secretagogue receptors (GHS-R) in the pituitary and hypothalamus and is a potent endogenous stimulator of GH release, operating through a pathway distinct from GHRH. It's why GH secretion is also influenced by nutritional status and sleep.

IGF-1: the downstream messenger

Most of GH's effects on tissue growth and metabolism are mediated indirectly through IGF-1. The liver is the main source of circulating IGF-1, but many tissues; bone, muscle, cartilage, also produce IGF-1 locally in response to GH signalling. IGF-1 acts through its own receptor (IGF-1R), a tyrosine kinase receptor structurally similar to the insulin receptor, which is why cross-reactivity between the insulin and IGF-1 signalling pathways is a recurring theme in metabolic research.

IGF-1 circulates in a ternary complex with IGF-binding protein 3 (IGFBP-3) and an acid-labile subunit (ALS). This complex extends IGF-1's half-life from minutes to hours, acting as a circulating reservoir. Clinically, IGF-1 levels are used as a proxy for integrated GH secretion because they're far more stable across the day than GH itself.

(I'll admit I got the IGF-1 binding protein numbering wrong for years, there are six IGFBPs, and IGFBP-3 is the dominant one in adults, but the others show up in tissue-specific contexts and it's easy to conflate them when you're speed-reading reviews.)

Synthetic GH, GH secretagogues, and the Australian regulatory framework

Recombinant human GH (rhGH, somatropin) has been available since the mid-1980s, produced through recombinant DNA technology after the shift away from cadaveric pituitary-derived GH; a shift prompted by the Creutzfeldt-Jakob disease cases that emerged in the late 1980s in patients who had received the cadaveric form. Somatropin is listed on the Australian Register of Therapeutic Goods (ARTG, see our ARTG glossary entry for more on how that register works) and is legally available only under a valid prescription.

Under the Therapeutic Goods (Poisons Standard) instrument, commonly called the Poisons Standard; somatropin sits as a Schedule 4 (prescription-only) substance for approved indications, including GH deficiency in children and adults, Turner syndrome, Prader-Willi syndrome, and several other conditions assessed by a qualified medical practitioner. Access outside approved pathways can occur through the TGA's Special Access Scheme or via an Authorised Prescriber arrangement, both of which require clinical justification.

The separate category of peptides marketed as GH secretagogues, synthetic compounds designed to stimulate endogenous GH release by acting on GHS-R or GHRH receptors, is where the regulatory picture becomes considerably more serious. Many of these compounds (various synthetic peptide sequences, non-peptide small molecules) are not approved therapeutic goods in Australia. Under the Therapeutic Goods Act 1989, supplying unapproved therapeutic goods; including peptides being marketed for their supposed physiological effects, is illegal, and the TGA has been actively enforcing this. The TGA has published multiple regulatory actions and warnings specifically addressing this category. There is no approved indication, no ARTG listing, and no lawful supply chain for these unapproved peptide products outside an approved clinical trial.

The subcutaneous injection route commonly associated with these compounds does not change their regulatory status. Route of administration is irrelevant to whether a product is lawfully supplied.

Honestly, the framing I see in some online spaces, treating these as a grey area; understates the enforcement reality considerably. The TGA's position is not ambiguous.

GH axis research: where the science actually sits

The genuine clinical literature on the GH/IGF-1 axis is substantial. Research into GH deficiency, acromegaly (pathological GH excess), and the role of IGF-1 in longitudinal growth has been published across decades of peer-reviewed endocrinology. The Endocrine Society's clinical practice guidelines on adult GH deficiency, for example, reflect a careful evidence base built on randomised controlled trials and long-term observational data.

Research into synthetic secretagogues, separate from approved therapies, is largely preclinical or early-phase. Where human trials have been conducted, they are typically small, short-duration, and measure surrogate endpoints (GH or IGF-1 pulse amplitude) rather than clinical outcomes. That's a meaningful limitation worth stating plainly, because the gap between "we observed a change in a biomarker" and "this produces a health benefit" is wide and not automatically bridged.

Between long runs along the Parramatta River I've been working back through some of the foundational GH pharmacokinetics literature from the 1990s, and the methodological care in those early studies is genuinely impressive; meticulous sampling schedules, careful accounting for the pulsatile secretion problem. The newer secretagogue literature doesn't always match that rigour, and I think that deserves more attention in science communication than it tends to get.

For a broader look at how peptide bonds determine the structural integrity, and metabolic vulnerability, of peptide therapeutics, our glossary entry on peptide bonds covers the chemistry in more detail. And if you're thinking about how bioavailability shapes the difference between oral and injectable peptide formats, that entry is worth reading alongside this one. The GLP-1 agonist class, covered in our GLP-1 receptor agonist entry, provides a useful comparison case for how peptide drugs navigate regulatory approval; a process that the GH secretagogue space has, so far, largely not completed in Australia.

Sources

• Peptides regulated as therapeutic goods, Therapeutic Goods Administration (TGA), Australian Government
• Growth Hormone, StatPearls, National Center for Biotechnology Information (NCBI/NIH)
• The GH/IGF-1 axis in ageing and longevity; Nature Reviews Endocrinology, via NCBI PMC
• TGA warns about peptide products not approved for human therapeutic use, Therapeutic Goods Administration (TGA), Australian Government

, Priya Nandakumar, Pharmacology writer, peptides & PK